电话:
+86 (0512) 65829739
传真:
+86 (010) 6788 5057
电子邮件:
orders@antibodies-online.cn

Recombinant PD-L1 抗体

The 小鼠 Bispecific anti-PD-L1 antibody is suitable to detect PD-L1 in samples from 小鼠. It has been validated for WB, FACS, IHC, ELISA, ICC 和 in vivo.
产品编号 ABIN7795533
发货至: 中国
Contact our Customer Service for availability and price in your country. Contact Info

Our Local Distributor

中国
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
4A Biotech Co.,Ltd.
Tel +86 (0512) 65829739 传真 +86 (010) 6788 5057

Quick Overview for Recombinant PD-L1 抗体 (ABIN7795533)

抗原

See all PD-L1 抗体
PD-L1 (CD274 (PD-L1))

抗体类型

Recombinant Antibody

适用

  • 259
  • 179
  • 74
  • 6
  • 6
  • 6
  • 5
  • 1
  • 1
  • 1
小鼠

宿主

  • 151
  • 124
  • 33
  • 26
  • 4
  • 4
  • 2
小鼠

克隆类型

  • 216
  • 116
  • 7
  • 3
Bispecific

标记

  • 164
  • 22
  • 19
  • 19
  • 15
  • 5
  • 5
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
This PD-L1 antibody is un-conjugated

应用范围

  • 187
  • 161
  • 82
  • 81
  • 40
  • 32
  • 31
  • 29
  • 21
  • 16
  • 11
  • 10
  • 9
  • 7
  • 7
  • 5
  • 3
  • 3
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (IHC), ELISA, Immunocytochemistry (ICC), In vivo Studies (in vivo)

质量等级

In vivo Grade

克隆位点

10F-9G2-1-29F-1A12-1
  • Expression System

    Mammalian cells

    原理

    In Vivo Grade Recombinant Anti-mouse PD-L1 / PD-1 Bispecific Antibody, Mouse IgG2c LALAPG Kappa (Clone 10F.9G2.1 / 29F.1A12.1)

    产品特性

    The rat anti-mouse PD-1 monoclonal antibody 29F.1A12 (rat IgG2a kappa) reacts with the mouse PD-1 protein (programmed death-1 or CD279) encoded by the mouse Pdcd1 gene, a member of the CD28 family of the Ig superfamily. PD-1 has two ligands, PD-L1 and PD-L2, both of which belong to the B7 family. It has been shown that in mouse models of melanoma, tumor growth can be transiently arrested via treatment with the anti-mouse PD-1 and anti-mouse PD-L1 antibodies which block the interaction between the PD-L1 protein and its receptor PD-1 protein. The 29F.1A12 monoclonal antibody blocks the binding of both the mouse PD-L1 protein and the mouse PD-L2 protein to the mouse PD-1 protein. The rat anti-mouse PD-L1 monoclonal antibody 10F.9G2 (rat IgG2b kappa) reacts with the mouse PD-L1 protein (programmed death ligand-1, B7-H1 or CD274), a member of the B7 family of the Ig superfamily. PD-1 has two ligands, PD-L1 and PD-L2. It has been shown that in mouse models of melanoma, tumor growth can be transiently arrested via treatment with the anti-mouse PD-1 and anti-mouse PD-L1 antibodies which block the interaction between the PD-L1 protein and its receptor PD-1 protein. The 10F.9G2 monoclonal antibody blocks the binding of the mouse PD-L1 protein to the mouse PD-1 protein. It is under investigation how the recombinant anti-mouse PD-1 / PD-L1 bispecific antibodies (29F.1A12 / 10F.9G2 and 10F.9G2 / 29F.1A12) behave different from the individual monoclonal antibodies and their combination (29F.1A12 + 10F.9G2). Our recombinant anti-mouse PD-1 / PD-L1 bispecific antibodies have a part (variable regions) or complete amino acid sequences of the rat anti-mouse PD-1 antibody (hybridoma clone name or number: 29F.1A12) and the rat anti-mouse PD-L1 antibody (hybridoma clone name or number: 10F.9G2).

    纯化方法

    Protein A or G affinity column

    纯度

    >95 % by reducing SDS-PAGE

    内毒素水平

    < 1 EU per 1 mg of the protein by the LAL method

    亚型

    IgG2c, L234A, L235A, P329G, kappa
  • 应用备注

    Optimal working dilution should be determined by the investigator.

    限制

    仅限研究用
  • 状态

    Liquid

    浓度

    > 3 mg/mL

    储存条件

    4 °C,-20 °C

    储存方法

    Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
  • 抗原

    PD-L1 (CD274 (PD-L1))

    别名

    PD-L1 & PD-1

    Sub Type

    Bispecific

    途径

    Cancer Immune Checkpoints
You are here: